

Speaker's Biosketch

ICoLA 2024

Yu Mi Kang (Harvard Medical School/TIMI Study Group, USA)

Dr. Yu Mi Kang is an endocrinologist specializing in cardiometabolic research with career experiences in both the Republic of Korea and the United States. She served as a faculty member at Asan Medical Center until 2019, pursuing epidemiologic research on cardiometabolic risk profiling. Following this, she advanced her career in the United States, focusing on large-scale clinical trial operations and the clinical investigation of novel therapies targeting individuals at high cardiometabolic risk. Currently, she is a senior fellow in the Division of Endocrinology, Diabetes, and Hypertension, and the TIMI Study Group at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, USA. With her team at the TIMI Study Group, Dr. Kang leads clinical trials of pharmacologic agents targeting cardiometabolic disorders such as obesity, type 2 diabetes mellitus, and dyslipidemia, and provides consultation services for earlier-phase trials. She also leads clinical research projects focused on cardiometabolic risk optimization through comprehensive risk stratification leveraging precision medicine approaches such as genetics, genomics, and biomarkers.